As part of the funding partnership of the ATIP-Avenir 2020 program, the ARC Foundation for Cancer Research awards a grant of 220,000 euros over three years to Frédéric Lagarrigue for his research on tumor-associated macrophages.
Frédéric Lagarrigue joined the Institute of Pharmacology and Structural Biology (IPBS) in Toulouse in 2019 as a CNRS researcher in immunology. His research aims to develop new approaches to target macrophage integrins in tumors and inflammatory diseases. F. Lagarrigue is laureate of the ATIP-Avenir 2020 funding program, led jointly by Inserm and CNRS, which enables talented young scientists to create and lead a team within an established laboratory in France. His new team, "Integrins in Immune Cells", will be officially launched at IPBS in January 2021.
As a partner of Inserm and CNRS, the ARC Foundation grants funding each year to a young cancer researcher within the framework of the ATIP-Avenir program. This year, the Scientific Council of the ARC Foundation selected F. Lagarrigue’s project both for its scientific quality and for its relevance in onco-immunology. The funding agreement between the CNRS and the ARC Foundation will allow F. Lagarrigue to hire a postdoctoral researcher for a period of three years and thus supports his work aimed at designing novel strategies for blocking macrophage infiltration into tumors to synergize with combination therapies that simultaneously neutralize both protumoral stromal cells and cancer cells.
Thanks to the generosity of its donors and testators, the ARC Foundation, recognized as being of public utility, allocates more than 26 million euros each year to research projects that bring hope to patients.